BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 38115126)

  • 21. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells.
    Zou ZQ; Zhang LN; Wang F; Bellenger J; Shen YZ; Zhang XH
    Mol Med Rep; 2012 Feb; 5(2):503-8. PubMed ID: 22101421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment.
    Sidorov M; Dighe P; Woo RWL; Rodriguez-Brotons A; Chen M; Ice RJ; Vaquero E; Jian D; Desprez PY; Nosrati M; Galvez L; Leng L; Dickinson L; Kashani-Sabet M; McAllister SD; Soroceanu L
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
    Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matrine induces senescence of human glioblastoma cells through suppression of the IGF1/PI3K/AKT/p27 signaling pathway.
    Zhou W; Wang J; Qi Q; Feng Z; Huang B; Chen A; Zhang D; Li W; Zhang Q; Bjerkvig R; Li X; Wang J
    Cancer Med; 2018 Sep; 7(9):4729-4743. PubMed ID: 30079478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
    Failly M; Korur S; Egler V; Boulay JL; Lino MM; Imber R; Merlo A
    Mol Cancer Ther; 2007 Feb; 6(2):773-81. PubMed ID: 17308073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
    Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
    Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
    Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in
    Ippen FM; Alvarez-Breckenridge CA; Kuter BM; Fink AL; Bihun IV; Lastrapes M; Penson T; Schmidt SP; Wojtkiewicz GR; Ning J; Subramanian M; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
    Clin Cancer Res; 2019 Jun; 25(11):3374-3383. PubMed ID: 30796030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
    Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.
    Sunayama J; Sato A; Matsuda K; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
    Neuro Oncol; 2010 Dec; 12(12):1205-19. PubMed ID: 20861085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
    Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
    Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
    Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C
    Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tenacissoside H repressed the progression of glioblastoma by inhibiting the PI3K/Akt/mTOR signaling pathway.
    Dong J; Qian Y; Zhang W; Xu J; Wang L; Fan Z; Jia M; Wei L; Yang H; Luo X; Wang Y; Jiang Y; Huang Z; Wang Y
    Eur J Pharmacol; 2024 Apr; 968():176401. PubMed ID: 38331340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme.
    Ramaiah MJ; Kumar KR
    Mol Biol Rep; 2021 May; 48(5):4813-4835. PubMed ID: 34132942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474).
    Lin L; Gaut D; Hu K; Yan H; Yin D; Koeffler HP
    Int J Oncol; 2014 Feb; 44(2):557-62. PubMed ID: 24297065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor effects of progesterone in human glioblastoma multiforme: role of PI3K/Akt/mTOR signaling.
    Atif F; Yousuf S; Stein DG
    J Steroid Biochem Mol Biol; 2015 Feb; 146():62-73. PubMed ID: 24787660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.